Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement

Author(s): Schröder FH,Roobol MJ, Boevé ER, de Mutsert R, Zuijdgeest-van Leeuwen SD, et al.

Abstract

Objectives:Epidemiological studies have shown significant relationships between the use of dietary components and prostate cancer incidence and mortality. Large studies of primary prevention, which confirm these findings, are desirable but costly and difficult to design. The present tertiary prevention study reports on the effect of a dietary supplement in comparison with placebo on the rate of increase of prostate-specific antigen (PSA).

Methods:49 patients with a history of prostate cancer and rising PSA levels after radical prostatectomy (n = 34) or radiotherapy (n = 15) participated in a randomised, double-blind, placebo-controlled crossover study of a dietary supplement. Ethical approval of the protocol was obtained. Treatment periods of 10 weeks were separated by a 4-week washout period. The supplement consisted of soy, isoflavones, lycopene, silymarin and antioxidants as main ingredients. Changes in the rate of increase of PSA (PSA slope and doubling time) were the primary parameters of efficacy. Analyses according to intention to treat (ITT) and per protocol (PP) were carried out.

Results:Baseline parameters did not differ between randomised groups. Five participants were lost to follow-up, however 46 could be evaluated in an ITT analysis. PP analysis could be performed in 42 men with at least 5 PSA measurements. Per protocol analysis showed a significant decrease in PSA slope (p = 0.030) and (2)log PSA slope (p = 0.041). This translates into a 2.6 fold increase in the PSA doubling time from 445 to 1150 days for the supplement and placebo periods. No treatment-based changes in safety parameters were observed during the study.

Conclusions:The soy-based dietary supplement utilised in this study was shown to delay PSA progression after potentially curative treatment in a significant fashion. More extensive studies of the supplement may be indicated.

Similar Articles

Role of lycopene and tomato products in prostate health

Author(s): Stacewicz-Sapuntzakis M, Bowen PE

Plant extracts: sense or nonsense?CurrOpinUrol 18: 16-20

Author(s): Madersbacher S, Berger I, Ponholzer A, Marszalek M

Lycopene inhibits the growth of normal human prostate epithelial cells in vitro

Author(s): Obermüller-Jevic UC,Olano-Martin E, Corbacho AM, Eiserich JP, van der Vliet A, et al.

Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostate

Author(s): Herzog A, Siler U, Spitzer V, Seifert N, Denelavas A, et al.

Lycopene inhibits disease progression in patients with benign prostate hyperplasia

Author(s): Schwarz S,Obermüller-Jevic UC, Hellmis E, Koch W, Jacobi G, et al.

Diet adherence dynamics and physiological responses to a tomato product whole-food intervention in African-American men

Author(s): Park E,Stacewicz-Sapuntzakis M, Sharifi R, Wu Z, Freeman VL, et al.

Lycopene and prostate cancer

Author(s): Barber NJ, Barber J

Tomatoes, lycopene, and prostate cancer: progress and promise

Author(s): Hadley CW, Miller EC, Schwartz SJ, Clinton SK

A food-based formulation provides lycopene with the same bioavailability to humans as that from tomato paste

Author(s): Richelle M,Bortlik K, Liardet S, Hager C, Lambelet P, et al.

A physiological pharmacokinetic model describing the disposition of lycopene in healthy men

Author(s): Diwadkar-Navsariwala V, Novotny JA, Gustin DM, Sosman JA, Rodvold KA, et al.

Combinations of tomato and broccoli enhance antitumor activity in dunning r3327-h prostate adenocarcinomas

Author(s): Canene-Adams K,Lindshield BL, Wang S, Jeffery EH, Clinton SK, et al.

Combined lycopene and vitamin E treatment suppresses the growth of PC-346C human prostate cancer cells in nude mice

Author(s): Limpens J,Schröder FH, de Ridder CM, Bolder CA, Wildhagen MF, et al.

Chemoprevention of prostate cancer with lycopene in the TRAMP model

Author(s): Konijeti R, Henning S, Moro A, Sheikh A, Elashoff D, et al.

Antioxidants block prostate cancer in lady transgenic mice

Author(s): Venkateswaran V,Fleshner NE, Sugar LM, Klotz LH

Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer

Author(s): Chan JM, Weinberg V, Magbanua MJ, Sosa E, Simko J, et al.

Lycopene effects on rat normal prostate and prostate tumor tissue

Author(s): Siler U, Herzog A, Spitzer V, Seifert N, Denelavas A, et al.

Effects of lycopene on protein expression in human primary prostatic epithelial cells

Author(s): Qiu X, Yuan Y, Vaishnav A, Tessel MA, Nonn L, et al.

Effect of lycopene on cell viability and cell cycle progression in human cancer cell lines

Author(s): Teodoro AJ, Oliveira FL, Martins NB, Maia Gde A, Martucci RB, et al.

A prospective study of lycopene and tomato product intake and risk of prostate cancer

Author(s): Kirsh VA,Mayne ST, Peters U, Chatterjee N, Leitzmann MF, et al.

Lycopene for the prevention of prostate cancer

Author(s): Ilic D, Forbes KM, Hassed C

A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk

Author(s): Bunker CH, McDonald AC, Evans RW, de la Rosa N, Boumosleh JM, et al.

Tomato sauce supplementation and prostate cancer: lycopene accumulation and modulation of biomarkers of carcinogenesis

Author(s): Bowen P, Chen L, Stacewicz-Sapuntzakis M, Duncan C, Sharifi R, et al.

Serenoarepens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH

Author(s): Morgia G, Russo GI, Voce S, Palmieri F, Gentile M, et al.